Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Internal Medicine

Background:

• Hypertension and hypercholesterolemia are primary risk factors for atherosclerotic coronary artery disease (CAD).
• Effective management of blood pressure and serum cholesterol is crucial for controlling CAD risk.
• Doxazosin is a selective alpha 1-adrenergic inhibitor used for essential hypertension treatment.

Purpose of the Study:

• To evaluate the impact of doxazosin on serum lipid parameters in patients with essential hypertension.
• To assess the effects of doxazosin on total cholesterol, triglycerides, and HDL cholesterol levels.
• To determine if doxazosin favorably influences key risk factors for coronary artery disease.

Main Methods:

• Conducted 10- to 12-week placebo-controlled studies comparing doxazosin (142 patients) with placebo (155 patients).
• Performed a 52-week study comparing doxazosin with atenolol.
• Measured serum lipid parameters: total cholesterol, total triglyceride, and HDL cholesterol.

Main Results:

• Doxazosin treatment showed an 8.9% increase in the HDL/total cholesterol ratio versus placebo (p<0.05).
• No significant differences in total cholesterol, HDL cholesterol, or triglyceride levels were observed compared to placebo.
• In the 52-week study, doxazosin significantly decreased triglycerides (5%, p<0.001) and increased HDL cholesterol (3.9%, p<0.01) and the HDL/total cholesterol ratio (5.4%, p<0.0001) compared to atenolol.

Conclusions:

• Doxazosin is an effective antihypertensive agent.
• Doxazosin demonstrates a favorable impact on serum lipid profiles, particularly the HDL/total cholesterol ratio.
• The drug's effects on blood pressure and lipids offer a beneficial impact on major CAD risk factors.